Piramal Pharma Limited (PPL) has released its FY2025 Sustainability Report, which highlights the company’s progress in integrating responsible practices across its operations worldwide. The report is themed “Innovating Responsibly, Growing Sustainably” and demonstrates measurable progress across four strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity.
The company has made significant progress in various areas, including strengthening governance frameworks, accelerating decarbonization, advancing diversity and inclusion, and enhancing community impact through its CSR programs. Some key achievements include a 6% reduction in Scope 1 & 2 emissions, a 7.8% increase in renewable energy adoption, and a 90% recycling target for non-hazardous waste.
Piramal Pharma has also made significant strides in diversity and inclusion, with 30% women representation on the Board and 20% women in the global workforce. The company has also launched various initiatives to promote stakeholder centricity, including a women-led! skill development program and a partnership with the Life Sciences Sector Skill Development Council.
The company’s CSR initiatives have had a significant impact, with outreach to 112 aspirational districts and investments of ₹5.34 crore in initiatives such as school infrastructure upgrades, teacher training, and public health campaigns. Employee volunteering has also supported various community projects, including plantation drives, health awareness sessions, and community projects.
Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that sustainability is a deliberate choice for the company and that they remain committed to innovating responsibly and growing sustainably for patients, communities, and the planet. The company’s commitment to sustainable growth is aligned with GRI standards, SASB, and UNGC frameworks, and the report demonstrates Piramal Pharma’s commitment to responsible capital allocation, sustainable operations, and impactful stakeholder engagement.
Some of the key statistics from the report include:
* 50% independent directors on the Board
* 30% women representation on the Board
* 26.5% of critical suppliers assessed on sustainability
* 36 regulatory inspections successfully completed
* 165 customer audits conducted globally
* 6% reduction in Scope 1 & 2 emissions
* 7.8% increase in renewable energy adoption
* 90% recycling target for non-hazardous waste
* 2.10 lakh kiloliters of freshwater conserved through water stewardship initiatives
* 2,000+ saplings planted
* 30% green cover maintained across Indian sites
Overall, Piramal Pharma’s FY2025 Sustainability Report demonstrates the company’s commitment to sustainability and responsible growth, and highlights its progress in various areas, including governance, diversity and inclusion, and community impact.